NeoGenomics(US:NEO)2025-10-28 11:09Revenue Performance - Total revenue for Q3 2025 increased 12% year-over-year to $188 million, driven by an 18% growth in clinical revenue[1][2] - NGS revenue grew 24% year-over-year and now represents nearly one-third of clinical revenue[1][2] - Net revenue for the three months ended September 30, 2025, was $187.8 million, a 11.8% increase from $167.8 million in the same period of 2024[20] - Total revenue for Q3 2025 reached $187.8 million, an increase of 11.9% compared to $167.8 million in Q3 2024[30] - For the nine months ended September 30, 2025, total revenue was $537.2 million, a 9.9% increase from $488.6 million in the same period of 2024[30] Profitability Metrics - Consolidated gross profit for Q3 2025 was $80 million, a 7% increase compared to Q3 2024, resulting in a gross profit margin of 43%[4][5] - Gross profit for Q3 2025 was $80.4 million, reflecting a 7.4% increase from $74.9 million in Q3 2024[30] - Adjusted net income for Q3 2025 was $3.6 million, compared to $6.9 million in Q3 2024, indicating a decrease of 47.4%[34] - Adjusted EBITDA for Q3 2025 was positive $12 million, a decline of 9% from the prior year[4][7] - Adjusted EBITDA for the three months ended September 30, 2025, was $12.2 million, compared to $13.4 million in the same period of 2024, a decrease of 9.0%[28] - Adjusted EBITDA for 2025 is forecasted to be between $41 million and $44 million[39] Expenses and Losses - Operating expenses for Q3 2025 were $107 million, reflecting a 12% increase compared to Q3 2024[6] - Total operating expenses for the three months ended September 30, 2025, were $107.5 million, up from $96.1 million in the same period of 2024, representing an increase of 11.5%[20] - Net loss for the quarter increased 53% to $27 million compared to a net loss of $18 million in Q3 2024[7] - The net loss for the nine months ended September 30, 2025, was $98.1 million, compared to a net loss of $63.4 million for the same period in 2024, indicating a deterioration of 54.8%[22] - The company expects a GAAP net loss in 2025 to be between $116 million and $108 million[39] Cash and Assets - Cash and cash equivalents totaled $164 million at the end of Q3 2025, down from $367 million at the end of FY 2024[7][18] - Total assets decreased to $1.375 billion as of September 30, 2025, from $1.638 billion at the end of FY 2024[18] - Cash and cash equivalents at the end of the period were $164.1 million, down from $362.0 million at the end of September 2024, a decline of 54.7%[22] Shareholder Metrics - The company reported a basic net loss per share of $0.21 for the three months ended September 30, 2025, compared to a loss of $0.14 per share in the same period of 2024[20] - The weighted average shares outstanding for the three months ended September 30, 2025, were 128.4 million, compared to 127.0 million in the same period of 2024[20] Research and Development - Research and development expenses for the nine months ended September 30, 2025, increased to $27.9 million from $23.2 million in 2024, an increase of 20.3%[20] Guidance and Projections - The company reaffirmed its full-year 2025 guidance, projecting consolidated revenue between $720 million and $726 million, a 9% to 10% increase from FY 2024[8] - Adjusted diluted EPS for 2025 is projected to be between $0.08 and $0.12[39]